Today Quoin is sharing additional data on that subject at 4 weeks post-discontinuation of treatment with QRX003. As the table below illustrates all of the positive clinical benefits observed after ...

The information for this report is sourced from a press release statement filed by Quoin Pharmaceuticals with the SEC. The stock currently trades at $0.41, near its 52-week low of $0.42, reflecting ...

After Discontinuation of Treatment with QRX003 Complete Reversal of Positive Clinical Improvements Across all Measured Endpoints ...

filing for QRX003 as potentially the first approved treatment for Netherton Syndrome.” Netherton Syndrome, a form of Ichthyosis, is a rare hereditary skin disorder caused by a mutation in the ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression ...

Treatment for sleep apnea aims to improve your breathing during sleep and reduce the risk of underlying health concerns. Common options include CPAP machines, oral devices, and lifestyle measures ...